As indicators of a pharmacological response, quantification and monitoring of PD biomarkers is of crucial importance, particularly for dose optimization studies during pre-clinical and clinical trials. Maximum information must be obtained from limited sample volumes.
The ability to quantify unbound target molecules on a nanoliter-scale platform suitable for both PK and PD analysis significantly boosts lab and instrument productivity.
Transform lab productivity, save analyst time
 |
 |
Multiple analytes measured in nanoliter volumes – low sample consumption |
|
|
Fast development - new assays can be running within days |
|
|
Fast turnaround - automation improves throughput, speeds up assay validation |
|
|
Fewer dilutions - broad dynamic range and reduced matrix effects |